Status:
COMPLETED
Association of Carbamylated HDL and CAD in T2DM Patients
Lead Sponsor:
RenJi Hospital
Collaborating Sponsors:
Ruijin Hospital
Conditions:
Type 2 Diabetes Mellitus With Circulatory Complciation
Eligibility:
All Genders
40-90 years
Brief Summary
This is an observational cross-sectional study aimed at investigating the alterations of the carbamylated-HDL levels in T2DM patients, and comparing the concentration of carbamylated-HDL between the T...
Detailed Description
High-density lipoprotein (HDL) is involved in various atheroprotective processes, including reverse cholesterol transport, inhibition of lipid oxidation and inflammatory cytokine secretion, endothelia...
Eligibility Criteria
Inclusion
- 1:Clinical diagnosis of T2DM (according to the criteria of the American Diabetes Association.)
Exclusion
- end-stage renal disease (ESRD)
- acute coronary syndrome,
- heart failure,
- chronic viral or bacterial infection,
- cancer,
- immune system disorders
Key Trial Info
Start Date :
September 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2019
Estimated Enrollment :
282 Patients enrolled
Trial Details
Trial ID
NCT04390711
Start Date
September 1 2018
End Date
March 30 2019
Last Update
May 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rui Jin Hospital
Shanghai, China